Avedro Inc., an ophthalmic pharmaceutical and medical device company based in Waltham, Mass., said Thomas Burns was elected to its board. Burns is president, CEO and a member of the board at Glaukos Corp.
Canbridge Life Sciences Ltd., a biopharmaceutical company based in Beijing, appointed May Orfali as chief medical officer, effective July 23, 2018. Orfali, who is based in Cambridge, Mass., replaced Mark Goldberg, who was acting as interim chief medical officer.
Histogenics Corp., a Waltham, Mass.-based developer of restorative cell therapies for pain relief and restored function, reported the appointment of Lynne Kelley as its chief medical officer.
McKesson Corp., of San Francisco, said Brian Tyler was appointed president and chief operating officer, effective Aug. 2, 2018. Previously chairman of the management board, McKesson Europe, Tyler has also served as president of McKesson North American Pharmaceutical Distribution and Services, McKesson U.S. Pharmaceutical, McKesson Medical-Surgical and McKesson Specialty Health, as well as executive vice president of corporate strategy and business development.